TABLE OF CONTENTS
Volume 8, Issue 2 (April 2008)
EELS (Ethical, Economic, Legal & Social) Paper
Ancillary risk information and pharmacogenetic tests: social and policy implications
N B Henrikson, W Burke and D L Veenstra
Pharmacogenomics J 8: 85-89; advance online publication, May 8, 2007; doi:10.1038/sj.tpj.6500457
Review
Pharmacogenetic studies in depression: a proposal for methodologic guidelines
A Serretti, M Kato and J L Kennedy
Pharmacogenomics J 8: 90-100; advance online publication, August 7, 2007; doi:10.1038/sj.tpj.6500477
Original Articles
A brain-derived neurotrophic factor (BDNF) haplotype is associated with antidepressant treatment outcome in mood disorders
M Gratacòs, V Soria, M Urretavizcaya, J R González, J M Crespo, M Bayés, R de Cid, J M Menchón, J Vallejo and X Estivill
Pharmacogenomics J 8: 101-112; advance online publication, May 15, 2007; doi:10.1038/sj.tpj.6500460
Catechol-O-methyltransferase (COMT) polymorphisms predict treatment response in electroconvulsive therapy
Sami Anttila, Kaija Huuhka, Martti Huuhka, Ari Illi, Riikka Rontu, Esa Leinonen and Terho Lehtimäki
Pharmacogenomics J 8: 113-116; advance online publication, August 14, 2007; doi:10.1038/sj.tpj.6500468
Apolipoprotein E polymorphism, homocysteine serum levels and hippocampal volume in patients with alcoholism: an investigation of a gene–environment interaction
J Wilhelm, H Frieling, N von Ahsen, T Hillemacher, J Kornhuber and S Bleich
Pharmacogenomics J 8: 117-121; advance online publication, April 10, 2007; doi:10.1038/sj.tpj.6500453
Genetic variation in the dopamine D4 receptor (DRD4) gene and smoking cessation: follow-up of a randomised clinical trial of transdermal nicotine patch
S P David, M R Munafò, M F G Murphy, M Proctor, R T Walton and E C Johnstone
Pharmacogenomics J 8: 122-128; advance online publication, March 27, 2007; doi:10.1038/sj.tpj.6500447
Epidermal growth factor receptor polymorphisms and clinical outcomes in non-small-cell lung cancer patients treated with gefitinib
G Liu, S Gurubhagavatula, W Zhou, Z Wang, B Y Yeap, K Asomaning, L Su, R Heist, T J Lynch and D C Christiani
Pharmacogenomics J 8: 129-138; advance online publication, March 20, 2007; doi:10.1038/sj.tpj.6500444
PXR, CAR and HNF4
genotypes and their association with pharmacokinetics and pharmacodynamics of docetaxel and doxorubicin in Asian patients
S Y Hor, S C Lee, C I Wong, Y W Lim, R C Lim, L Z Wang, L Fan, J Y Guo, H S Lee, B C Goh and T Tan
Pharmacogenomics J 8: 139-146; advance online publication, September 18, 2007; doi:10.1038/sj.tpj.6500478
Deletion polymorphism of the UGT2B17 gene is associated with increased risk for prostate cancer and correlated to gene expression in the prostate
A-H Karypidis, M Olsson, S-O Andersson, A Rane and L Ekström
Pharmacogenomics J 8: 147-151; advance online publication, March 27, 2007; doi:10.1038/sj.tpj.6500449
Hepatocyte nuclear factor-1 alpha is associated with UGT1A1, UGT1A9 and UGT2B7 mRNA expression in human liver
J Ramírez, S Mirkov, W Zhang, P Chen, S Das, W Liu, M J Ratain and F Innocenti
Pharmacogenomics J 8: 152-161; advance online publication, April 17, 2007; doi:10.1038/sj.tpj.6500454
Association of tumor necrosis factor-
–308G>A polymorphism with IgE-mediated allergy to betalactams in an Italian population
R-M Guéant-Rodriguez, J-L Guéant, M Viola, D Tramoy, F Gaeta and A Romano
Pharmacogenomics J 8: 162-168; advance online publication, May 1, 2007; doi:10.1038/sj.tpj.6500456
